Drug Database
Back to search

Iceland· IS-EU/1/18/1296/001-002

Tegsedi

A inotersen product containing inotersenum inn, registered in Iceland by Akcea Therapeutics Ireland Ltd. The same ATC class is registered in 9 of our 19 countries.

ATC N07XX15

Checked against Icelandic Medicines Agency (Iceland) on

Informational only — not a medical device.

SOURCE REGISTER · ISIcelandic Medicines Agency (Iceland)normalisedTegsediATCN07XX15REGISTER NO.IS-EU/1/18/1296/001-0…PACKS LISTED0CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about inotersenum innAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Inotersen is registered in 9 of 19 countries.

Countries holding a registration under ATC N07XX15 (inotersen), each read from that country’s own register.

  • This record: Iceland, from Icelandic Medicines Agency (Iceland)
  • 6 of them publish a price we can compare per daily dose
Search inotersen products by name

Inotersen · ATC N07XX15

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Netherlands
  • Polandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

Icelandic Medicines Agency (Iceland)
Active substance
Inotersenum INN
Manufacturer
Akcea Therapeutics Ireland Ltd
Country
Iceland (IS)
ATC code
N07XX15
ATC class
Inotersen
Defined daily dose
41 mg, P
Reimbursed
Not published by this register
Source register
Icelandic Medicines Agency (Iceland)
Last checked
September 29, 2026

Packs & prices · 0

No packs listed by the register for this record.

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

169 interactions on record for inotersen.

Graded by severity as the source publishes them — 143 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check inotersen against other medicinesHow interaction checks work

Inotersen · interactions on record

169 records

  • 143 severe
  • 26 moderate

Most severe, free to view

  • HeparinB01AB01severe
  • NeomycinA07AA01severe
  • StreptomycinA07AA04severe
  • Polymyxin BA07AA05severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Inotersen in 8 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All inotersen products

Authorised across Europe · EMA

The same active substance is authorised in 2 EEA countries. Names it is sold under:

  • Liechtenstein · Tegsedi
  • Norway · Tegsedi

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/355850c7-191f-4446-9bff-4edb58dd60bf
GET /v1/drugs/355850c7-191f-4446-9bff-4edb58dd60bf?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Stungulyf, lausn í áfylltri sprautu",
  "source": "lyfjastofnun",
  "atc_raw": "N07XX15",
  "marketed": false,
  "strength": "284 mg",
  "ma_number": "EU/1/18/1296/001-002",
  "substance": "Inotersenum INN",
  "other_info": "Ávísun lyfsins er bundin við sérfræðinga í taugasjúkdómum.\r\nMarkaðssetning á Íslandi er háð því að Lyfjastofnun hafi staðfest að sérstök skilyrði er varða öryggi og verkun við notkun lyfsins séu uppfyllt.",
  "legal_status": "(R Z) Sérfræðingsmerkt (og lyfseðilsskylt)",
  "ma_issued_serial": "43287"
}
API referenceMCP serverPlans

See everything about inotersen.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console